As with all observational studies, we cannot eliminate the possibility of unmeasured (eg, IBD severity and proteinuria) and residual (eg, doses of immunomodulators) confounders that might have affected the association between incident TNF inhibitor use and outcomes. The gene discussed is TNF; the disease is inflammatory bowel disease.